Results of drought treatments comparison within Mg levels and soybean genotypes. by Amanda Soares Santos (16962244)

Time kill kinetics of WSWE against <i>S</i>. <i>globosa</i>. by Acharya Balkrishna (5640038)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

“…<i>parva</i> cells treated with different concentrations of MeJA (10, 20, 50, 100 μM) and GA3 (10, 20, 50, 100 μM). …”

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

“…<i>parva</i> cells treated with different concentrations of MeJA (10, 20, 50, 100 μM) and GA3 (10, 20, 50, 100 μM). …”

Original images of HE staining, transmission electron microscopy, and fluorescence. by Cao Wang (1500691)

Subjects:

Body and absolute and relative organ weights of rats post PM2.5 exposure (‾χ±s, n =  8). by Cao Wang (1500691)

Subjects:

Animal phenotype raw data. by Cao Wang (1500691)

Subjects:

Alterations in the post-PM2.5 exposure sperm quality ( ±s). by Cao Wang (1500691)

Subjects:

TLC photography of fungal extract. by Shivankar Agrawal (11565095)

Subjects:

Fig 5 - by Shivankar Agrawal (11565095)

Subjects:

Effect of Safr and Cands on the gene expression level of monoamine oxidase (MAO-A, fold change) and (MAO-B, fold change) as well as the activities of monoamine oxidase (MAO, μM 4-H... by Nagwa Ibrahim Shehata (17319689)

Subjects:

IC₅₀ of indole alkaloid against lipase [23]. by Atikarn Janthongkaw (17020498)

S1 Dataset - by Nelmo Jordão Manjate (16324619)

“…For diagnosis by nasal Ag-RDTs, Panbio was MZN 547.00 (USD 8.90), COVIOS was MZN 768.00 (USD 12.50), and LumiraDx was MZN 798.00 (USD 13.00). Medical supplies expenditures represented the main driver of the final cost (>50%), followed by personnel and overhead costs (mean 15% for each). …”

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Cry variables. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Developing a straightforward and effective strategy to modify antimicrobial peptides (AMPs) is crucial in overcoming the challenges posed by their instability and toxicity. …”

The phosphorylation sites we identified in both ULK1 and ATG13 are conserved between different isoforms. by Zhiyuan Li (205620)